tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared to Sandimmune. 2001 Nov-Dec Transplant. Proc. pmid:11750465
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Uchida K et al. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. 1998 Transplant. Proc. pmid:9636518
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Facundo C et al. Results of a triple induction regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. 2002 Transplant. Proc. pmid:11959203
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Klupp J et al. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. 1998 Transplant. Proc. pmid:9636585
Fujikawa K et al. Effects of tacrolimus on rat thymic epithelial cells. 2000 Transplant. Proc. pmid:11120046
Jordan ML et al. Tacrolimus-based immunosuppression in pediatric renal transplantation. 1999 Transplant. Proc. pmid:10576039
Martín-Mateos RM et al. Initial immunosuppression with or without basiliximab: a comparative study. 2012 Transplant. Proc. pmid:23146457
Nakamuta M et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. 2005 Transplant. Proc. pmid:16387179
Kim HC et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. 2004 Transplant. Proc. pmid:15518753
Ohtsuka S et al. Effect of splenectomy on hamster-to-rat pancreas xenotransplantation. 1994 Transplant. Proc. pmid:7518109
Porayko MK et al. Comparing nephrotoxicity of FK 506 and cyclosporine regimens after liver transplantation: preliminary results from US Multicenter trial. U.S. Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533358
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Yang YJ et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. 2008 Transplant. Proc. pmid:18589147
Jain A et al. Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival. 2002 Transplant. Proc. pmid:12176467
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Brunet M et al. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. 1998 Transplant. Proc. pmid:9865298
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Bouchta NB et al. Conversion from tacrolimus to cyclosporin is associated with a significant improvement of glucose metabolism in patients with new-onset diabetes mellitus after renal transplantation. 2005 Transplant. Proc. pmid:15919485
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Velio P et al. Combined orthotopic liver-small bowel transplantation or small bowel transplantation in pigs: relations between survival, rejection, and mucosal morphometry. 1997 Transplant. Proc. pmid:9142295
Varo E et al. Incidence of cytomegalovirus infection and disease in orthotopic liver transplant patients immunosuppressed with cyclosporin versus tacrolimus. 2002 Transplant. Proc. pmid:12176488
Song Z et al. Protective effect of FK-506 in pig-to-rat islet xenotransplantation is abrogated by prednisolone. 2000 Transplant. Proc. pmid:10936332
Morozumi K et al. Electron-microscopic peritubular capillary lesion is a specific and useful diagnostic indicator for chronic rejection of renal allografts showing less specific morphologic lesions in the cyclosporine era. 1997 Feb-Mar Transplant. Proc. pmid:9123167
Nishioka T et al. Arterial stiffness after successful renal transplantation. 2008 Transplant. Proc. pmid:18790249
Sola E et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. 2002 Transplant. Proc. pmid:12176537
Utsugi R et al. Tolerance across a two-haplotype, fully MHC-mismatched barrier induced in miniature swine renal allografts treated with a 12-day course of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11266727
Shinozuka H et al. Effect of FK 506 on experimental liver carcinogenesis. 1991 Transplant. Proc. pmid:1721407
Wu MS et al. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. 1999 Feb-Mar Transplant. Proc. pmid:10083527
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Lorenzini S et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. 2006 Transplant. Proc. pmid:16797338
Quiroga I et al. Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267261
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Dumortier J et al. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience. 2010 Transplant. Proc. pmid:20832553
Yonan NA et al. Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. 1998 Transplant. Proc. pmid:9723443
Greenstein SM et al. Nifedipine prevents tacrolimus-induced intestinal hemodynamic and functional impairments. 1998 Transplant. Proc. pmid:9745540
Valenzuela M et al. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report. 2008 Transplant. Proc. pmid:19010242
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Soh KS et al. Simultaneous liver and kidney transplantation from different living donors. 2012 Transplant. Proc. pmid:22410057